With all the noise and attention on marquee trials involving targeted therapies and immuno-oncology at cancer conferences lately, it’s all to easy to forget about numerous early stage developments making stealthier progress.

In this review we highlight another half a dozen such developments, which may be worth taking note of.

Not all of them will successfully make it to phase 3 trials so what can we learn about the latest available clinical data?

To learn more from our latest oncology review and get a heads up on key cancer research insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by